Article
Primary therapy for prostate cancer does not reduce the frequency of end-of-life urologic procedures, according to the findings of a population-based study.
Published OASIS data show durable efficacy of Revi System for UUI
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
Neoantigen cancer vaccine shows encouraging activity in ccRCC
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Genomic subtyping may help predict clinical outcomes in bladder cancer
FDA Updates in Urology: January 2025